Astellas entered into an agreement to develop and market compounds from CoMentis' beta-secretase inhibitor programme to treat Alzheimer's disease, the drugmakers announced. The deal, which includes early-stage candidate CTS-21166, could be worth up to $760 million for CoMentis.
Under the terms of the agreement, Astellas will pay CoMentis an upfront payment of $80 million and make a $20 million equity investment in the company. CoMentis will also be eligible for up to $660 million in milestone payments. Astellas will have the global commercialisation rights to products developed under the collaboration, while CoMentis will have the right to co-promote in the US where profit will be shared.
To read more Top Story articles, click here.